WASHINGTON — Withdrawal is becoming a habit for U.S. Rep. Tom Marino, President Donald Trump’s two-time nominee for national drug czar.

Mr. Marino, R-Lycoming, took himself out of consideration Tuesday, two days after news reports alleged that a bill that he pushed through last year was intentionally designed to undermine the Drug Enforcement Administration’s efforts to police opioid distribution. The congressman denied that in a written statement late Tuesday.

In it, Mr. Marino, a former prosecutor, confirmed his “difficult decision” to withdraw and said he had dedicated his life to law enforcement. But he added that “the best course of action is to remove the distraction my nomination has created to the utterly vital mission” of the Office of National Drug Control Policy.

It was the second time Mr. Marino has backed out of consideration to head the Office of National Drug Control Policy. Mr. Trump previously nominated him in the spring but he withdrew, citing his mother’s poor health, which has since stabilized.

Advertise with us

Mr. Trump nominated him again last month and he accepted, but he changed his mind again Tuesday after concerns arose about whether he sponsored a law intentionally designed to protect pharmaceutical distributors who flood the market with the narcotics that are fueling the nation’s opioid epidemic.

Mr. Trump first revealed the decision Tuesday in an early morning tweet that praised Mr. Marino as a “fine man and a great Congressman!”

He withdrew because he didn’t want to be seen as having “the perception of a conflict of interest with drug companies,” the president later told Fox News Radio’s Brian Kilmeade.

“There was a couple of articles having to do with him and drug companies. I will tell you, he felt compelled — he feels very strong about the opioid problem and the drug problem, which is a worldwide problem. It’s a problem that we have,” Mr. Trump said. “Tom Marino said, ‘Look, I’ll take a pass. I have no choice. I really will take a pass. I want to do it.’ He was very gracious, I have to say that.”

Concerns were brought to light by a joint investigation by The Washington Post and “60 Minutes” that raised concerns that Mr. Marino’s Ensuring Patient Access and Effective Drug Enforcement Act was designed to weaken federal drug policing.

Advertise with us

In his statement Tuesday, Mr. Marino defended the legislation and blamed the media for unbalanced reporting even though he had declined to give his side until now. His office took two days to respond to press inquires this week, and he called Capitol police when The Washington Post and “60 Minutes” tried to interview him in his office, the newspaper reported.

“This landmark legislation will help to facilitate a balanced solution for ensuring those who genuinely needed access to certain medications were able to do so, while also empowering the Drug Enforcement Agency to enforce the law and prevent the sale and abuse of prescription drugs," he wrote.

The law, which slid through Congress last year on voice votes, limits the DEA’s ability to block suspicious shipments to pharmacies. Previously, the DEA could intervene in cases of “imminent danger” but under the new law it now must show a “substantial likelihood of immediate threat.” That’s a standard that enforcers say is nearly impossible to meet.

No one — including Democrats now critical of Mr. Marino’s role — opposed the measure when it came before the House and Senate last year. They now say it’s because they didn’t understand the implications and thought the measure would merely fix technical language in existing law.

Democrats in both Washington and Pennsylvania said Mr. Marino’s advocacy for the legislation to help opioid distributors disqualify him from being drug czar.

Advertise with us

“Someone who wants to make it more difficult for authorities to take action is unequipped for the role, and would be counterproductive to fighting opioid addiction in this country,” said Jay Costa of Forest Hills, state Senate Democratic leader. “The congressman’s long record of capitulating to drug manufacturers and pharmaceutical lobbyists has made it easier for doctors and pharmacies to over-prescribe painkillers, putting opioids into the hands of people who can easily become addicted.”

A spokesman for U.S. Sen. Pat Toomey, R-Pa., defended Mr. Marino and pointed out that former Democratic President Barack Obama signed the law now under scrutiny.

“It’s ridiculous to think that Tom Marino and Barack Obama conspired to exacerbate the opioid crisis,” said the spokesman, Steve Kelly. “If there is an unintended or unforeseen consequence of this legislation, Sen. Toomey is open to working across the aisle to find a solution.”

U.S. Sen. Claire McCaskill, D-Mo., has promised to sponsor legislation to repeal the law.

U.S. Sen. Joe Manchin, D-W.Va., who was the first lawmaker to publicly call for Mr. Marino’s withdrawal, said he supports repeal of “this horrible law.”

Advertise with us

In a statement Tuesday he said he was thankful to the president for “recognizing that we need real leadership at the ONCDP and recognizing that Tom Marino was not it.”

The Democratic Congressional Committee said Mr. Marino’s withdrawal does nothing to demonstrate that Republicans are taking the opioid epidemic seriously and noted that the president still hasn’t made good on repeated promises to declare the crisis a national emergency.

“Trump has yet to offer any meaningful solutions, just more political bluster,” DNC spokesman Daniel Wessel said.

Mr. Marino, a fourth-term Republican from Williamsport, represents parts of central and northeastern Pennsylvania that are among the hardest hit by the opioid epidemic.

CORRECTION: A previous version of this article had misidentified the DEA as the Drug Enforcement Agency. The DEA, in fact, is an administration not an agency.

Washington Bureau Chief Tracie Mauriello: tmauriello@post-gazette.com; 703-996-9292 or on Twitter @pgPoliTweets. Staff writer Julian Routh contributed.